These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 710555)

  • 21. Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors.
    Fambrough DM; Drachman DB; Satyamurti S
    Science; 1973 Oct; 182(4109):293-5. PubMed ID: 4742736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Experimental autoimmune myasthenia gravis.
    Lindstrom J
    J Neurol Neurosurg Psychiatry; 1980 Jul; 43(7):568-76. PubMed ID: 6249892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myasthenia gravis (first of two parts).
    Drachman DB
    N Engl J Med; 1978 Jan; 298(3):136-42. PubMed ID: 201840
    [No Abstract]   [Full Text] [Related]  

  • 24. [Myasthenia gravis in newborn infants--pathological mechanism, clinical symptomatology and therapeutic procedures].
    Krauze M; Musialik E; Swietliński J; Litwa K; Latko E; Górny J; Sobczyk J
    Wiad Lek; 1992 Aug; 45(15-16):610-4. PubMed ID: 1488831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Characteristics of the neuromuscular defect in myasthenia (review)].
    Gekhm BM
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1969; 69(1):139-44. PubMed ID: 4891871
    [No Abstract]   [Full Text] [Related]  

  • 26. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
    Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ
    Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neonatal experimental autoimmune myasthenia gravis.
    Sanders DB; Cobb EE; Winfield JB
    Muscle Nerve; 1978; 1(2):146-50. PubMed ID: 571528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody to acetylcholine receptor increases degradation of junctional and extrajunctional receptors in adult muscle.
    Reiness CG; Weinberg CB; Hall ZW
    Nature; 1978 Jul; 274(5666):68-70. PubMed ID: 661996
    [No Abstract]   [Full Text] [Related]  

  • 29. The role of acetylcholine receptor antibodies in myasthenia gravis.
    Appel SH; Elias SB; Chauvin P
    Fed Proc; 1979 Sep; 38(10):2381-5. PubMed ID: 478014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myasthenia gravis: a personal view of pathogenesis and mechanism, part 2.
    Simpson JA
    Muscle Nerve; 1978; 1(2):151-6. PubMed ID: 220530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of acetylcholine receptor in rat diaphragm by anti-receptor sera.
    Heinemann S; Merlie J; Lindstrom J
    Nature; 1978 Jul; 274(5666):65-8. PubMed ID: 661995
    [No Abstract]   [Full Text] [Related]  

  • 32. Experimental autoimmune myasthenia gravis: can pretreatment with 125I-labeled receptor prevent functional damage at the neuromuscular junction?
    Sterz RK; Biro G; Rajki K; Filipp G; Peper K
    J Immunol; 1985 Feb; 134(2):841-6. PubMed ID: 2578165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acetylcholine receptor turnover in mice with passively transferred myasthenia gravis. I. Receptor degradation.
    Wilson S; Vincent A; Newsom-Davis J
    J Neurol Neurosurg Psychiatry; 1983 May; 46(5):377-82. PubMed ID: 6101171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myasthenia gravis induced by monoclonal antibodies to acetylcholine receptors.
    Lennon VA; Lambert EH
    Nature; 1980 May; 285(5762):238-40. PubMed ID: 6154894
    [No Abstract]   [Full Text] [Related]  

  • 35. The biology of myasthenia gravis.
    Drachman DB
    Annu Rev Neurosci; 1981; 4():195-225. PubMed ID: 7013636
    [No Abstract]   [Full Text] [Related]  

  • 36. Acetylcholine release in myasthenia gravis: regulation at single end-plate level.
    Plomp JJ; Van Kempen GT; De Baets MB; Graus YM; Kuks JB; Molenaar PC
    Ann Neurol; 1995 May; 37(5):627-36. PubMed ID: 7755358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The acetylcholine receptor in normal and pathologic states. Immunoperoxidase visualization of alpha-bungarotoxin binding at a light and electron-microscopic level.
    Bender AN; Ringel SP; Engel WK
    Neurology; 1976 May; 26(5):477-83. PubMed ID: 177905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survivin as a potential mediator to support autoreactive cell survival in myasthenia gravis: a human and animal model study.
    Kusner LL; Ciesielski MJ; Marx A; Kaminski HJ; Fenstermaker RA
    PLoS One; 2014; 9(7):e102231. PubMed ID: 25050620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antigenic modulation of junctional acetylcholine receptor is not sufficient to account for the development of myasthenia gravis in receptor immunized mice.
    Berman PW; Heinemann SF
    J Immunol; 1984 Feb; 132(2):711-7. PubMed ID: 6690616
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myasthenia gravis and acetylcholine receptor: autoimmunity and steroid effects.
    Abramsky O
    Int J Neurol; 1980; 14(1):25-34. PubMed ID: 6293989
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.